TABLE 1.

SWOT (strengths, weaknesses, opportunities and threats) analysis: creation of a Tuberculosis (TB) Vaccine Accelerator Council (TB VAC)

Strengths

TB VAC will address and proactively tackle the adverse impact of COVID-19 on TB ervices

TB VAC encourages global collaboration among funders, global health agencies, the private sector and  governments

TB VAC is getting high-level support from eminent global health leaders, such as Dr Tedros Adhanom  Ghebreyesus, the Director-General of the World Health Organization

Weaknesses

TB VAC will need to find solutions for the complex scientific and technical challenges related to vaccine  efficacy, safety and immunological responses

TB VAC requires huge resources and adequate funding for successful establishment and day-to-day operation

Navigating the time-consuming and challenging regulatory and approval processes for vaccine development  can be difficult

Achieving sufficient manufacturing capacity and a robust supply chain for TB vaccines can be challenging

Inadequate skilled researchers, laboratories and infrastructure may impact progress

Access to target populations: the logistics of reaching and vaccinating affected populations, particularly in  low-income and middle-income countries could be enormous

Opportunities

Improved TB prevention: development of effective vaccines to reduce global TB cases including  drug-resistant cases and deaths

Global health impact: potential to significantly impact global health by accelerating TB vaccine development

Threats

Insufficient funding: inadequate financial resources could impede the successful establishment and  operation of the TB VAC

Scientific challenges: overcoming scientific bottlenecks related to vaccine efficacy, safety, and immunological  responses